Nomura Securities Downgrades Macrocure Ltd (MCUR) to Neutral

Credit Suisse Downgrades Macrocure Ltd (MCUR) to Neutral

Credit Suisse downgraded Macrocure Ltd (NASDAQ: MCUR) from Outperform to Neutral with a price target of $5.00 (from $15.00).

Analyst M. Keeler commented, "We're downgrading MCUR to Neutral from Outperform following disappointing VLU data which will in the best case delay US approval by... More

Jefferies Downgrades Macrocure Ltd (MCUR) to Hold

Jefferies downgraded Macrocure Ltd (NASDAQ: MCUR) from Buy to Hold with a price target of $6.00 (from $14.00).

For an analyst ratings summary and ratings history on Macrocure Ltd click here. For more ratings news on Macrocure Ltd click here.

Shares of Macrocure Ltd closed at $12.05 yesterday.

UPDATE: Oppenheimer Downgrades Macrocure Ltd (MCUR) to Perform

(Updated - August 20, 2015 9:42 AM EDT)

Oppenheimer downgraded Macrocure Ltd (NASDAQ: MCUR) from Outperform to Perform and removed its price target (prior $20.00). The change follows news venous leg ulcer study is not expected to meet its primary endpoint.

Analyst Steven Lichtman... More

Macrocure (MCUR) Phase III Trial of CureXcell in Venous Leg Ulcers Doesn't Meet Primary Endpoint

Macrocure Ltd. (NASDAQ: MCUR) announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell® the Company's lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) determined that this study is not expected to meet its primary endpoint.

"While we are disappointed with the results of the VLU futility analysis, given the positive clinical outcomes seen in our experience with more than 5,000 patients in Israel, we continue to believe that the technology has clinical merit for patients with... More